Cybrexa Therapeutics
Victor Facchini is a finance professional with extensive experience in financial planning and analysis across various sectors, including pharmaceutical and biotechnology industries. As the Director of FP&A at Cybrexa Therapeutics since April 2023, Victor is involved in developing innovative cancer treatments. Prior roles include FP&A Manager at Nelson Laboratories, where Victor drove improvements in financial processes, and Senior Project Accountant at Ironstate Development Company, managing a $650MM portfolio. Victor's career also includes significant positions at Merck and Organon, where financial leadership spanned global drug development, strategic planning, and compliance. Victor holds a Bachelor of Commerce in Finance, Economics, and Management from York University, along with an Accounting Diploma from Seneca Polytechnic.
This person is not in any teams
This person is not in any offices
Cybrexa Therapeutics
1 followers
Cybrexa Therapeutics is developing an entirely new class of small molecule DNA repair inhibitors that directly target the tumor microenvironment. This approach leverages a novel tumor-localizing peptide technology developed by an internationally recognized research laboratory at Yale. Our approach will change the paradigm of drug delivery, and itwill greatly enhance the therapeutic index. It has the potential to re-define the definition of “drug-like,” which will unlock a vast array of molecules for clinical development. Our collection of tumor-localizing DNA repair inhibitors can be combined with numerous chemotherapies and also radiotherapy, allowing the safe delivery of higher drug doses, with enhanced efficacy.